GHRS Key Statistics, Chart & Performance
The current stock price of GHRS is 12.6 USD. In the past month the price decreased by -14.17%. In the past year, price increased by 79.56%.
GHRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.72 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.72B | ||
| MRK | MERCK & CO. INC. | 12.09 | 264.42B | ||
| PFE | PFIZER INC | 7.81 | 142.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.35 | 111.53B | ||
| ZTS | ZOETIS INC | 19.9 | 55.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.56 | 22.67B | ||
| VTRS | VIATRIS INC | 5.28 | 14.18B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.27 | 11.10B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.73 | 8.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.71B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.36B |
Related stock screener links
About GHRS
Company Profile
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 50
Phone: 35314378334
GH RESEARCH PLC / GHRS FAQ
Can you describe the business of GH RESEARCH PLC?
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
What is the stock price of GH RESEARCH PLC today?
The current stock price of GHRS is 12.6 USD. The price decreased by -1.41% in the last trading session.
What is the dividend status of GH RESEARCH PLC?
GHRS does not pay a dividend.
How is the ChartMill rating for GH RESEARCH PLC?
GHRS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is GHRS stock listed?
GHRS stock is listed on the Nasdaq exchange.
What do analysts say about GH RESEARCH PLC (GHRS) stock?
15 analysts have analysed GHRS and the average price target is 30.98 USD. This implies a price increase of 145.89% is expected in the next year compared to the current price of 12.6.
GHRS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS is one of the better performing stocks in the market, outperforming 90.03% of all stocks.
GHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. The financial health of GHRS is average, but there are quite some concerns on its profitability.
GHRS Financial Highlights
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 6.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.21% | ||
| ROE | -14.73% | ||
| Debt/Equity | 0 |
GHRS Forecast & Estimates
15 analysts have analysed GHRS and the average price target is 30.98 USD. This implies a price increase of 145.89% is expected in the next year compared to the current price of 12.6.